Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675059 | 1.00 | MAOB (0.50) | MAOBBCHEACHEPSMB1PSMB5 | |
| SCHEMBL12930770 | 0.98 | MAOB (0.49) | MAOBBCHEACHEPSMB1PSMB5 | |
| SCHEMBL15257178 | 0.94 | MAOB (0.46) | MAOBBCHEACHEPSMB1PSMB5 | |
| SCHEMBL9242050 | 0.85 | PTPN1 (0.40) | — | |
| SCHEMBL5864259 | 0.76 | MCHR1 (0.55) | PSMB1PSMB5PSMB2 | |
| SCHEMBL5864125 | 0.73 | HRH3 (0.47) | PSMB1PSMB5PSMB2 | |
| SCHEMBL5863668 | 0.72 | KDR (0.60) | — | |
| SCHEMBL5863736 | 0.70 | EPHX2 (0.46) | PSMB1PSMB5PSMB2ESR1ESR2 | |
| SCHEMBL25191698 | 0.69 | APP (0.53) | MAOBBCHEACHEPSMB5ESR1 | |
| SCHEMBL9172509 | 0.69 | APP (0.53) | MAOBBCHEACHEPSMB5ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389548-B2 | Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators | ENDORECHERCHE, INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389548-B2 | Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators | ENDORECHERCHE, INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8188066-B2 | Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators | ENDORECHERCHE, INC. (CA) | 2012-05-29 | — | — | US | disclosed |
| US-7943603-B2 | Medical treatment for conditions such as osteoporosis or breast cancer | ENDORECHERCHE, INC. (CA) | 2011-05-17 | — | — | US | disclosed |
| US-20100317635-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ENDORECHERCHE, INC. (CA) | 2010-12-16 | — | — | US | disclosed |
| US-7429576-B2 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7429576-B2 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-20070027122-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027122-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027124-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027124-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ESRRA, ESR2, ESRRG | MAOB 2486/4885BCHE 1557/4885ACHE 2390/4885 |
| US-20100317635-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | SHBG, CYP19A1, KISS1R | MAOB 1643/4885BCHE 128/4885ACHE 51/4885 |
| US-20070027122-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ESRRA, ESR2, ESRRG | MAOB 2486/4885BCHE 1557/4885ACHE 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.